This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
4, 2025 Riverain Technologies recently announced it expanded across eight countries in 2024 and added nearly 50 new customers with its ClearRead solutions to clearly, confidently and quickly detect cardiothoracic diseases. tim.hodson Tue, 02/04/2025 - 16:21 Feb.4,
What does the future of heartdisease detection look like? Strange dives into how EchoSolv leverages cutting-edge technology to tackle one of cardiology's most challenging conditions. EchoSolv, the groundbreaking AI platform developed by Echo IQ, is revolutionizing the detection of aortic stenosis. In this video, Prof.
When a patient needs a new heart valve, the current mechanical and tissue replacements each have strengths and weaknesses. Now, a team of researchers believe they have found a way to harness the strengths of both technologies in a way that could be life-changing -- and life-saving -- for many.
This clears the way for faster collaboration with other ultrasound systems, so the technology can reach more patients sooner. Heartdisease is the number one killer worldwide, and echocardiography is the first step to receiving a diagnosis and proper treatment.
The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. This new technology, invested in by Baptist Health Lexington, along with the expertise of their staff; will continue to help so many Kentuckians just like me.
milla1cf Wed, 03/06/2024 - 18:48 March 6, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heartdisease, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration ( FDA ) for its Coronary Artery Disease ( CAD ) Staging System.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Hearttechnology is in clinical use in the UK, European Union, and Australia.
Researchers from Rutgers Health and RWJBarnabas Health have developed an artificial intelligence (AI) technology that transforms basic electrocardiogram (ECG) readings of electrical activity into sophisticated heart motion signals normally obtained via echocardiogram, potentially improving how heartdisease is detected and monitored.
Congenital heart defects are the most common type of birth defect, affecting 1% of live births. The underlying cause of congenital heartdisease is frequently unknown. However, advances in human genetics and genome technologies have helped expand congenital heartdisease pathogenesis knowledge during the last few decades.
Researchers have developed a "blood vessel-on-a-chip" for heartdisease with the potential to change the future of drug testing and development. The technology could also reduce our reliance on animal testing.
In the age of technology, wearable devices have revolutionized how we approach health and wellness. Among their many benefits, wearable tech has proven to be a game-changer in monitoring heart health, particularly for individuals managing cardiovascular conditions or preparing for minimally invasive or bloodless heart surgery.
6, 2025 Medtronic plc hasannounced it received CE ( Conformit Europenne ) Mark for the Harmony Transcatheter Pulmonary Valve (TPV) System, a minimally invasive alternative to open-heart surgery for congenital heartdisease patients with native or surgically repaired right ventricular outflow tract (RVOT). Eur J Heart Fail.
25 saw a deluge of pharmaceutical solutions across the spectrum of heartdisease, from HCM all the way to LDL (detection and treatment just have to catch up). Among dozens of highlights, here are Cardiac Wires seven biggest trends from ACC.25. Diverse Pharma ACC.25 The post The Top Trends of ACC.25
The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.
The risk of being born with a major heart defect is 36% higher in babies who were conceived after assisted reproductive technology, such as in vitro fertilization (IVF), according to results of a very large study.
Henry Ford Health's Center for Structural HeartDisease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. She is only the third patient in the U.S. to receive the device. William O’Neill, M.D.
Personalized text messages effectively promoted increased physical activity for patients after significant heart events -- such as a heart attack or surgery -- but those effects later diminished.
mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024 — Heart Test Laboratories, Inc. AI-ECG is set to change the detection of heartdisease and this latest patent further bolsters value to HeartSciences and our stakeholders.” GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.
With the continuous progress of science and technology, artificial intelligence (AI) has become an important driving force for a new round of scientific and technological revolution and industrial change. In recent years, the attempts of AI to run through the whole process of CCTA have expanded the application scope of CCTA.
This technology can make blood pressure monitoring more accessible and convenient, especially for underserved populations. Researchers have developed a groundbreaking smartphone app that measures blood pressure using a smartphone's built-in sensors, eliminating the need for traditional cuffs.
Attendees can join with their peers and participate in sessions on structural heartdisease, congenital heartdisease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heartdisease, debates and games and early career topics.
New Guidelines on Peripheral Artery Disease Issued by American Heart Association, American College of Cardiology and Leading Medical Societies 4. Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5.
Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heartdisease. Challenges related to the use of wearables are common to every clinical setting, but specific topics for consideration in congenital heartdisease are highlighted.
This approach has specific benefits in cardiology, especially when dealing with complex cases like heartdisease, where long-term management and frequent monitoring are crucial. Technological barriers , including outdated or incompatible systems. Regulatory issues that may limit how data can be shared between institutions.
Scientists showed that, with help from an AI tool, cardiologists can diagnose heart attacks using a simpler, easier and more accessible electrocardiogram technology. But these ECGs require specialized equipment and expertise, and not all clinics have the capability to perform them.
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
iRhythm Technologies Receives European Union’s CE Marking Under Medical Device Regulation (EU MDR) for its Zio monitor and ZEUS System 3. Novel AI Platform Matches Cardiologists in Detecting Rheumatic HeartDisease 7. Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk 9.
milla1cf Wed, 01/31/2024 - 17:10 January 31, 2024 — Royal Philips , a global leader in health technology, announced that its latest TEE transducer, designed to serve more patients with improved overall comfort, has received FDA 510(k) clearance. In structural heartdisease, the quality of a 3D TEE image can help save lives.
Measuring the heart rate of great apes in captivity is essential for both health management and animal studies. Now, researchers have investigated the potential of using millimeter-wave radar technology to estimate heart rate from subtle body movements in chimpanzees.
No, CRISPR gene editing technology is not going to “cure” heartdisease. But a New York Times story by Gina Kolata on an extremely early study in animals prominently plays up just this extremely unlikely claim.
The clipping spline (mesh) is defined by the control points (green) and provides a smooth cutaway view into the looping embryonic mouse heart, revealing the blood flow (orange and blue) in the hearts atrium and ventricle. Faubert and Shang Wang, Stevens Institute of Technology tim.hodson Tue, 01/28/2025 - 10:45 Jan.
These results pave the way for integration into wearable technologies, allowing early interventions and better patient outcomes. Researchers have recently developed a deep-learning model capable of predicting the transition from a normal cardiac rhythm to atrial fibrillation.
The company notes that it provides a technology platform and clinical support services that integrate directly into primary care workflows, empowering providers to better coordinate care and close care gaps at lower overall costs, all while reducing administrative burden.
As patient expectations rise and technology advances, engaging patients effectively has never been more crucial to delivering top-tier care. In 2025, the demand for telehealth capabilities will only continue to grow, especially in managing chronic conditions like hypertension and heartdisease. GEMMS ONE V7.8,
a med tech company dedicated to helping patients with persistent ischemic heartdisease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain. T45 Labs is a specialized medical technology innovation company located in Santa Clara, Silicon Valley, CA.
Cardiac imaging technologies are increasing rapidly and are becoming increasingly important in helping the growing congenital heartdisease (CHD) population who are being treated with more complex surgical and catheter-based procedures, according to a JACC Scientific Statement published Jan. 1 in JACC.
Ventricular tachycardia (VT) ablations in patients with structural heartdisease remain challenging procedures with non-trivial rates of acute and short-term complications and VT recurrences, due, in part, to the inherent limitations on size and depth of ventricular lesions produced by existing RF and focal cryo catheters.
Journal of the American Heart Association, Volume 13, Issue 2 , January 16, 2024. BackgroundThe Active Community Case Management Platform is a cloud‐based technology developed to facilitate rheumatic heartdisease case management by health care providers.
For now, though, many challenges remain, and few AI tools have been proven to improve care, according to a new American Heart Association scientific statement published today in Circulation , the Association’s flagship, peer-reviewed journal. to ensure safety and effectiveness to mitigate harm as technologies rapidly evolve.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content